Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan

被引：0
|
作者：
Taku Kobayashi
Masato Hoshi
Akira Yuasa
Shoko Arai
Mitsunobu Ikeda
Hiroyuki Matsuda
Seok-Won Kim
Toshifumi Hibi
机构：
[1] Kitasato University Kitasato Institute Hospital,Center for Advanced IBD Research and Treatment
[2] Pfizer Japan Inc.,Inflammation and Immunology Medical Affairs
[3] Pfizer Japan Inc.,Health and Value
[4] IQVIA Solutions Japan K.K.,HEOR, Real World Evidence Solutions
来源：
PharmacoEconomics | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：589 / 604
页数：15
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naive Patients with Moderate-to-Severe Ulcerative Colitis in Japan
    Kobayashi, Taku
    Hoshi, Masato
    Yuasa, Akira
    Arai, Shoko
    Ikeda, Mitsunobu
    Matsuda, Hiroyuki
    Kim, Seok-Won
    Hibi, Toshifumi
    PHARMACOECONOMICS, 2023, 41 (05) : 589 - 604
  • [2] Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
    Luis Hernandez
    Hiroyo Kuwabara
    Anshul Shah
    Kaoru Yamabe
    Heather Burnett
    Kyle Fahrbach
    Maria Koufopoulou
    Ryuichi Iwakiri
    PharmacoEconomics, 2020, 38 : 69 - 84
  • [3] Effectiveness and Safety of Tofacitinib in Biologic-Naïve Elderly Patients with Ulcerative Colitis
    Singh D.m., A.
    Midha, V
    Bhardwaj, A.
    Sharma, R.
    Singh, D.
    Mahajan, R.
    Sood, A.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1678 - i1678
  • [4] Effectiveness and safety of vedolizumab and infliximab in biologic-naïve patients with moderate-to-severe ulcerative colitis: A multicenter, retrospective cohort study
    Meng, Rui Ping
    Huang, Bao Bao
    Wei, Yan Ling
    Lyu, Lin
    Yang, Huan
    Liu, Cheng
    Zhou, Hong Li
    Liao, Xi Ping
    Zhou, Jian Yun
    Xie, Xia
    JOURNAL OF DIGESTIVE DISEASES, 2024, 25 (04) : 230 - 237
  • [5] Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naive Patients with Moderate-to-Severe Ulcerative Colitis in Japan
    Hernandez, Luis
    Kuwabara, Hiroyo
    Shah, Anshul
    Yamabe, Kaoru
    Burnett, Heather
    Fahrbach, Kyle
    Koufopoulou, Maria
    Iwakiri, Ryuichi
    PHARMACOECONOMICS, 2020, 38 (01) : 69 - 84
  • [6] COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER BIOLOGIC FAILURE OR INTOLERANCE IN SPAIN
    Menchen, L.
    de Andres-Nogales, F.
    Garcia, S.
    Sanchez-Guerrero, A.
    Menchen, B.
    Cabez, A.
    Gomez, S.
    Lopez, A.
    Casado, M. A.
    Peral, C.
    Taxonera, C.
    VALUE IN HEALTH, 2019, 22 : S619 - S619
  • [7] COST-EFFECTIVENESS OF FIRST-LINE BIOLOGICS FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS
    Beilman, Candace L.
    Fedorak, Richard N.
    Halloran, Brendan P.
    GASTROENTEROLOGY, 2019, 156 (06) : S260 - S261
  • [8] COST-EFFECTIVENESS OF BIOLOGICS FOR MODERATE TO SEVERE ULCERATIVE COLITIS IN BRAZIL
    Brito, N.
    Mulinari, E.
    VALUE IN HEALTH, 2020, 23 : S146 - S146
  • [9] COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN GREECE
    Vellopoulou, K.
    Stefanou, G.
    Tzanetakos, C.
    Boubouchairopoulou, N.
    Nakou, M.
    Kourlaba, G.
    VALUE IN HEALTH, 2019, 22 : S619 - S620
  • [10] COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN COLOMBIA
    Hansen, Tawnya
    Mak, Joyce
    Underwood, Fox
    Windsor, Joseph
    King, James
    Quan, Joshua
    Buie, Michael
    Coward, Stephanie
    Frolkis, Alex
    Leung, Alexander
    Ma, Christopher
    Novak, Kerri
    Panaccione, Remo
    Qian, Yiming
    Burisch, Johan
    Gearry, Richard
    Ng, Siew
    Kaplan, Gilaad
    INFLAMMATORY BOWEL DISEASES, 2022, 28 : S44 - S44
12345